Diagonal Therapeutics
Updated: January 08, 2026
CEO - Alex Lugovskoy
Country: USA | Funding: $253M (+)
Founded: 2022
Website: https://www.diagonaltx.com
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
Founded: 2022
Website: https://www.diagonaltx.com
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
